New Market Report: Market and Product Forecasts: Depression - Further Clinical Failures Dampen Growth Prospects
New product launches across the seven major markets will see the market expand incrementally to 2020, reinforcing the depression market's status as one of the largest of the CNS disorders. Lu AA21004 (Lundbeck/Takeda) will become the highest-selling drug, after negative clinical trial data for TC-5214 (Targacept/AstraZeneca) and the discontinuation of Valdoxan (agomelatine; Servier) in the US.
View full press release